<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39332537</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>231</Volume><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Large-scale deep learning identifies the antiviral potential of PKI-179 and MTI-31 against coronaviruses.</ArticleTitle><Pagination><StartPage>106012</StartPage><MedlinePgn>106012</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2024.106012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(24)00221-3</ELocationID><Abstract><AbstractText>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to the global pandemic of Coronavirus Disease (2019) (COVID-19), underscoring the urgency for effective antiviral drugs. Despite the development of different vaccination strategies, the search for specific antiviral compounds remains crucial. Here, we combine machine learning (ML) techniques with in vitro validation to efficiently identify potential antiviral compounds. We overcome the limited amount of SARS-CoV-2 data available for ML using various techniques, supplemented with data from diverse biomedical assays, which enables end-to-end training of a deep neural network architecture. We use its predictions to identify and prioritize compounds for in vitro testing. Two top-hit compounds, PKI-179 and MTI-31, originally identified as Pi3K-mTORC1/2 pathway inhibitors, exhibit significant antiviral activity against SARS-CoV-2 at low micromolar doses. Notably, both compounds outperform the well-known mTOR inhibitor rapamycin. Furthermore, PKI-179 and MTI-31 demonstrate broad-spectrum antiviral activity against SARS-CoV-2 variants of concern and other coronaviruses. In a physiologically relevant model, both compounds show antiviral effects in primary human airway epithelial (HAE) cultures derived from healthy donors cultured in an air-liquid interface (ALI). This study highlights the potential of ML combined with in vitro testing to expedite drug discovery, emphasizing the adaptability of AI-driven approaches across different viruses, thereby contributing to pandemic preparedness.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Horst</LastName><ForeName>Demi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Aarhus University, Department of Biomedicine, Aarhus C, 8000, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter-Timofte</LastName><ForeName>Madalina E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Aarhus University, Department of Biomedicine, Aarhus C, 8000, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danneels</LastName><ForeName>Adeline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL- Center for Infection and Immunity of Lille, Lille, 59000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva da Costa</LastName><ForeName>Leandro</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Aarhus University, Department of Biomedicine, Aarhus C, 8000, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurmasheva</LastName><ForeName>Naziia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Aarhus University, Department of Biomedicine, Aarhus C, 8000, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thielke</LastName><ForeName>Anne L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Aarhus University, Department of Biomedicine, Aarhus C, 8000, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Anne Louise</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Aarhus University, Department of Biomedicine, Aarhus C, 8000, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chorošajev</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cortex Discovery, München, 81673, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holm</LastName><ForeName>Christian K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Aarhus University, Department of Biomedicine, Aarhus C, 8000, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belouzard</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL- Center for Infection and Immunity of Lille, Lille, 59000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Weber</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cortex Discovery, München, 81673, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beny</LastName><ForeName>Cedric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cortex Discovery, München, 81673, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olagnier</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Aarhus University, Department of Biomedicine, Aarhus C, 8000, Denmark. Electronic address: olagnier@biomed.au.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral compounds</Keyword><Keyword MajorTopicYN="N">Artificial intelligence</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronaviruses</Keyword><Keyword MajorTopicYN="N">Deep neural network</Keyword><Keyword MajorTopicYN="N">Drug repurposing</Keyword><Keyword MajorTopicYN="N">Large-scale deep learning</Keyword><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">MTI-31</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">PKI-179</Keyword><Keyword MajorTopicYN="N">Pi3K</Keyword><Keyword MajorTopicYN="N">SARS-CoV</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">mTOR</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>13</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>13</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39332537</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2024.106012</ArticleId><ArticleId IdType="pii">S0166-3542(24)00221-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>